<DOC>
	<DOCNO>NCT02336425</DOCNO>
	<brief_summary>This study plan assess effect reduction rate severe asthma exacerbation different dose level QGE031 asthma patient inadequately control inhaled steroid plus beta-2 agonist medication without oral steroid . However , study terminate due efficacy result interim analysis ( end treatment epoch ) Phase II study CQGE031B2201 ( NCT01716754 ) . Planned data analysis perform study due early termination limit dataset ( 10 participant receive study medication 440 participant plan ) .</brief_summary>
	<brief_title>Efficacy Safety QGE031 Compared With Placebo Patients Aged 18-75 Years With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Key A diagnosis allergic asthma , uncontrolled current medication . History least 2 asthma exacerbation last 1 year Forced Expiratory Volume one second ( FEV1 ) ≥ 40 % ≤ 80 % predict normal value ; reversibility follow administration bronchodilator . Key Use tobacco product within previous 6 month ( Social occasional smoker may include ) . Recent asthma attack/exacerbation asthma worsening/ respiratory infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Asthma</keyword>
</DOC>